Overview of the FDA and NIH Joint Virtual Training Program

The FDA's CDER, through its Small Business and Industry Assistance (SBIA) office, will host a series of three virtual training sessions on ClinicalTrials.gov for staff at academic medical centers on July 14, 22, and 30, 2026 (1:00 PM - 2:00 PM ET). The sessions will be co-led by FDA and NIH experts and will consist of pre-recorded videos followed by live panel discussions. A key differentiator from previous webinars is the provision of tailored guidance from each of the CDER, CBER, and CDRH centers.

Key Training Topics: Registration, Reporting, and Corrective Actions

The training will be structured around three main tracks. First, it will cover the timelines and submission requirements for clinical trial registration and results reporting, as outlined in FDAAA 801 and 42 CFR Part 11. Second, it will analyze common registration errors and reporting omissions made by academic institutions and present best practices for quality control. Third, representatives from each center will directly explain the regulatory nuances for different product types, including drugs (CDER), biological products (CBER), and medical devices (CDRH).

Background of Increased Regulatory Enforcement: Surge in Fines and Warning Letters

Violations of FDAAA 801 can result in civil penalties of up to $10,000 per day until corrective action is completed, and may also lead to the revocation or suspension of federal research funding. In FY 2025, the number of warning letters issued by CDER increased by 50% compared to the previous year, exceeding 125, with clinical trial integrity being a top enforcement priority. A survey of academic institutions revealed that only 43% have a registration policy and only 35% have a results reporting policy, indicating a clear need for systematic training.

ClinicalTrials.gov Platform Transition and Timing

The NLM (National Library of Medicine) is currently modernizing the ClinicalTrials.gov PRS (Protocol Registration and Results System), and new records will no longer be possible in the classic PRS starting in July 2026. The timing of this training is no coincidence, as it is designed to coincide with this transition. In the fall of 2026, all protocol submissions will be consolidated into the modernized PRS, and in 2027, the classic results section, API, and XML upload functionality will be phased out.

Practical Impact on Academic Institutions and the Biopharmaceutical Industry

ClinicalTrials.gov has over 500,000 registered clinical trials, and data transparency directly impacts FDA approval reviews, insurance coverage decisions, and investor due diligence. While approximately 90% of those notified by the FDA voluntarily take corrective action, the remaining 10% have official violations recorded in their clinical trial records, which can damage the institution's reputation. By internalizing regulatory compliance capabilities, academic medical centers can expand opportunities for collaboration with sponsor companies and enhance their competitiveness in securing research funding.